Lenacapavir and the persistent challenge of HIV eradication: Biological barriers, therapeutic innovation, and future research directions
Gowdham Pannirselvam*
Senior Nurse Educator, Kauvery Hospital, Marathahalli, Banglore
*Correspondence
Abstract
Despite remarkable progress in antiretroviral therapy, Human Immunodeficiency Virus (HIV) infection remains incurable, necessitating lifelong treatment and sustained public health intervention. The inability to eradicate HIV is rooted in unique viral and host-related factors, including genomic integration, viral latency, rapid mutation, and immune system disruption. Conventional antiretroviral agents effectively suppress viral replication but fail to eliminate latent reservoirs, highlighting the need for novel therapeutic strategies. Lenacapavir, a first-in-class capsid inhibitor with long-acting properties, represents a significant advancement in HIV treatment and prevention by targeting a highly conserved viral structure and disrupting multiple stages of the viral life cycle. This review examines the biological reasons underlying the persistence of HIV, evaluates the mechanism of action and clinical significance of Lenacapavir, and explores emerging research pathways aimed at achieving sustained viral remission and eventual cure. The integration of long-acting capsid inhibitors with reservoir-targeting and immune-based strategies may redefine the future landscape of HIV therapeutics.
Key words: Human Immunodeficiency Virus (HIV); Lenacapavir; Antiretroviral Therapy (ART)
HIV is very complex
Viral Biology and Lifecycle
Human Immunodeficiency Virus possesses a unique and complex lifecycle that fundamentally limits the ability of the host immune system and current therapies to eliminate infection. HIV primarily targets CD4⁺ T lymphocytes, macrophages, and dendritic cells by binding to the CD4 receptor and co-receptors CCR5 or CXCR4. Following entry into the host cell, the viral RNA genome is reverse transcribed into DNA and subsequently integrated into the host cell genome through the action of the viral integrase enzyme. This integration event is irreversible and establishes a permanent proviral state, enabling the virus to persist indefinitely within infected cells. Once integrated, the viral genome may remain transcriptionally silent, thereby escaping immune detection and pharmacologic intervention. Because infected host cells are not readily distinguished from uninfected cells, the immune system cannot selectively eradicate them without causing extensive collateral damage, making complete viral clearance biologically unattainable with current immune mechanisms.
High Mutation Rate
A defining characteristic of HIV that contributes substantially to treatment failure and vaccine development challenges is its extraordinarily high mutation rate. The viral reverse transcriptase enzyme lacks proofreading capability, resulting in frequent replication errors during viral genome synthesis. This leads to rapid accumulation of mutations and the generation of genetically diverse viral populations, or quasi species, within a single host. Such genetic variability enables HIV to rapidly adapt to selective pressures imposed by host immune responses and antiretroviral drugs. Consequently, escape mutations can arise that diminish antibody recognition, reduce cytotoxic T lymphocyte effectiveness, and confer resistance to antiretroviral agents. This evolutionary flexibility allows HIV to evade long-term immune control and represents a critical obstacle to both durable therapy and vaccine development.
Viral Latency and Reservoirs
HIV establishes latent reservoirs early during infection, primarily in long-lived memory CD4⁺ T cells, but also in macrophages and other tissue compartments. These latently infected cells harbour integrated proviral DNA but do not actively produce viral particles, rendering them invisible to immune surveillance and unaffected by antiretroviral drugs that target active viral replication. While antiretroviral therapy effectively suppresses plasma viremia to undetectable levels, it does not eliminate latent provirus. If treatment is interrupted, viral replication resumes rapidly from these reservoirs, leading to systemic rebound viremia. As a result, lifelong antiretroviral therapy is required to maintain viral suppression. The existence of these stable reservoirs is widely recognized as the principal barrier to curing HIV infection.
Immune Evasion
HIV employs multiple mechanisms to evade host immune defences, further complicating eradication efforts. The virus directly infects and progressively depletes CD4⁺ T helper cells, which play a central role in coordinating adaptive immune responses. This immune system impairment compromises both humoral and cellular immunity. Additionally, HIV envelope proteins are heavily glycosylated, forming a “glycan shield” that masks key epitopes and prevents effective antibody neutralization. Continuous viral mutation further alters antigenic targets, allowing HIV to evade recognition by neutralizing antibodies and cytotoxic T lymphocytes. These immune evasion strategies render HIV a constantly moving target, severely limiting the effectiveness of vaccines and immunotherapeutic approaches.
Overview of Antiretroviral Therapy (ART)
Evolution of ART
The development of antiretroviral therapy represents one of the greatest achievements in modern medicine. Early treatment strategies relied on nucleoside reverse transcriptase inhibitors (NRTIs), which were later supplemented by non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors, and integrase strand transfer inhibitors. The use of combination antiretroviral therapy targeting multiple stages of the viral lifecycle has proven highly effective in suppressing viral replication, restoring immune function, reducing HIV-related morbidity and mortality, and preventing transmission. As a result, individuals living with HIV who maintain virologic suppression can now achieve near-normal life expectancy, and population-level viral suppression has become a central goal of global HIV control strategies.
Limitations of Conventional ART
Despite its success, conventional antiretroviral therapy has notable limitations. Treatment typically requires strict daily adherence, which may be compromised by pill burden, adverse effects, treatment fatigue, social stigma, and socioeconomic barriers. Long-term therapy can also be associated with metabolic complications, cardiovascular risk, renal dysfunction, and drug–drug interactions. In cases of suboptimal adherence or inadequate drug exposure, incomplete viral suppression allows for the emergence of drug-resistant strains of HIV. These limitations highlight the need for novel drug classes with improved resistance profiles, enhanced durability, and long-acting formulations, thereby setting the stage for the development of agents such as Lenacapavir.
Lenacapavir: A First-in-Class Capsid Inhibitor
How Lenacapavir Works
Lenacapavir is a first-in-class antiretroviral agent that targets the HIV capsid, a structural protein essential for viral replication and survival. Unlike traditional antiretroviral drugs that inhibit viral enzymes, Lenacapavir binds at a conserved interface between capsid protein subunits. This unique binding disrupts capsid dynamics by inducing “lethal hyper stabilization,” in which the capsid becomes excessively stable and unable to properly disassemble after viral entry. Proper capsid uncoating is essential for reverse transcription and transport of viral DNA into the host cell nucleus; disruption of this process effectively blocks early stages of infection. In addition, Lenacapavir interferes with late stages of viral replication by impairing capsid assembly and maturation, resulting in the production of structurally abnormal, non-infectious virions. By acting across multiple stages of the viral lifecycle, Lenacapavir presents a high genetic barrier to resistance, making viral escape through single mutations less likely.
Unique Advantages
Lenacapavir offers several advantages over existing antiretroviral therapies. It exhibits no cross-resistance with established ART classes, allowing its use in patients with extensive drug resistance. The drug’s long-acting formulation permits subcutaneous administration once every six months, significantly improving adherence and reducing treatment burden. Clinical studies have demonstrated its efficacy in heavily treatment-experienced individuals with multidrug-resistant HIV, highlighting its value in populations with limited therapeutic options.
Lenacapavir in Clinical Trials and Real-World Data
Treatment Studies
The CAPELLA trial, a pivotal phase II/III study, evaluated Lenacapavir in heavily treatment-experienced individuals with multidrug-resistant HIV. The trial demonstrated rapid and substantial reductions in viral load following initiation of Lenacapavir, with sustained virologic suppression observed at 26 weeks when combined with optimized background therapy. These findings confirmed both the potency and durability of capsid inhibition in advanced HIV disease.
Source: Xu, Shujing & Zhan, Peng. (2024).
Prevention (PrEP) Studies
Lenacapavir has also shown exceptional efficacy in HIV prevention. Phase III PURPOSE-2 trial results demonstrated a 96% reduction in new HIV infections compared with background incidence. Additional studies reported near-complete protection among women, underscoring the drug’s potential impact in high-risk populations. Lenacapavir has received strong regulatory support for prevention use from major health authorities, including the FDA and WHO.
Comparative Effectiveness
Comparative analyses indicate that Lenacapavir-based prevention strategies outperform daily oral PrEP regimens in populations where adherence to daily medication is challenging. The long-acting injectable approach provides consistent drug exposure and minimizes missed doses, contributing to superior real-world effectiveness.
Challenges and Considerations in Lenacapavir Use
Resistance
Although Lenacapavir has a high barrier to resistance, certain capsid mutations, such as Q67H and N74D, have been associated with reduced drug susceptibility. Continuous resistance surveillance and the use of Lenacapavir in combination regimens remain essential to preserve long-term efficacy.
Access and Equity
Global access to Lenacapavir is influenced by cost, manufacturing capacity, regulatory approvals, and the availability of generic formulations. In some regions, regulatory delays and pricing constraints may limit timely access, potentially exacerbating health inequities.
Limitations
Lenacapavir is not curative and must be used in combination with other antiretroviral agents. Its long half-life may complicate resistance management if dosing schedules are interrupted, necessitating careful clinical monitoring and patient education.
Future Research Directions
Long-Acting Therapies
Future research aims to develop even longer-acting formulations, including annual injections, oral long-acting prodrugs, and implantable delivery systems, further reducing treatment burden.
Cure Strategies
Cure-oriented research focuses on targeting latent reservoirs through “shock and kill” approaches using latency-reversing agents, as well as “block-and-lock” strategies designed to permanently silence proviral transcription. Gene-editing technologies such as CRISPR-based approaches are being investigated to excise or inactivate integrated viral DNA.
Vaccine Development
HIV vaccine development remains a global priority. Insights gained from capsid structure and function may inform the design of novel immunogens capable of inducing broader and more durable immune responses.
Combination Approaches
Combining capsid inhibitors with immune modulators or broadly neutralizing antibodies represents a promising strategy to enhance immune control and reduce viral persistence.
Expanding to HIV-2 and Other Retroviruses
Preliminary data suggest potential activity of capsid inhibitors against HIV-2 and related retroviruses, though further research is required to confirm efficacy and optimize treatment strategies.
Conclusion
HIV remains exceptionally difficult to eliminate due to its integration into host DNA, establishment of latent reservoirs, rapid mutation, and direct impairment of immune function. While antiretroviral therapy has achieved durable viral suppression, it has not overcome the fundamental biological mechanisms that allow HIV persistence. Lenacapavir represents a major therapeutic innovation by targeting the HIV capsid and disrupting multiple stages of the viral life cycle while offering long-acting dosing that improves adherence and prevention efficacy. Although not curative, Lenacapavir significantly advances the field of HIV treatment and prevention and provides a foundation upon which future cure-directed strategies may be built. Continued integration of capsid inhibitors with reservoir-targeting, immune-based, and gene-directed therapies offers the most promising pathway toward sustained viral remission and eventual eradication of HIV.
References
- Siliciano RF, Greene WC. HIV latency. Cold Spring Harb Perspect Med. 2011;1(1):a007096.
- Chun TW, et al. Persistence of HIV in resting CD4⁺ T cells. Nature. 1997; 387:183–188.
- Deeks SG, et al. Towards an HIV cure. Nat Rev Immunol. 2021; 21:367–379.
- Flexner C. Antiretroviral drug development. Nat Rev Drug Discov. 2007; 6:959–966.
- Link JO, et al. Clinical targeting of HIV capsid protein with Lenacapavir. Nature. 2020; 584:614–618.
- Daar ES, et al. Lenacapavir in multidrug-resistant HIV (CAPELLA trial). N Engl J Med. 2022; 386:1793–1803.
- Margolis DM, et al. HIV latency and cure strategies. Nat Rev Microbiol. 2020; 18:587–598.
- Fauci AS, et al. Ending the HIV pandemic. Science. 2021; 373:141–145.
- Hsu DC, et al. Long-acting antiretroviral therapy. Clin Infect Dis. 2023; 76:1124–1131.
- Corey L, et al. HIV prevention research. N Engl J Med. 2024; 390:1–11.
